IDDRIVE https://validator.w3.org/feed/docs/rss2.html Studies id.DRIVE launches pilot study to assess potential underestimation of RSV, hMPV, and PIV detection rates. Study documents and tools Home Study Contributors id.DRIVE announces strategic expansion of study network to Canada Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies The id.DRIVE partnership starts a viral respiratory infections surveillance study in adults hospitalised for severe acute respiratory infection in Europe id.DRIVE partners gather in Leuven for the 2025 Steering Committee meeting id.DRIVE celebrates 5 years of advancing respiratory infectious diseases and vaccine research in Europe id.DRIVE showcases RSV research at ReSViNET 2026 conference in Italy IDWeek 2025 New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe ESWI Conference 2025 Prof. Philippe Beutels joined id.DRIVE’s Independent Scientific Committee ReSVINET 2026 ESCMID Global 2026 EFSPI Vaccine Statistic Workshop First face-to-face COVIDRIVE Steering Committee meeting AstraZeneca has published its first COVIDRIVE results in Lancet Regional Health Europe. COVIDRIVE has reached a milestone: enrolment of over 10,000 patients id.DRIVE has activated a new Study Contributor (study site) in Italy id.DRIVE welcomes 3 new members to its Independent Scientific Committee The id.DRIVE studies reach 25,000 patients — A major milestone on our mission to build a large and sustainable platform for respiratory pathogens and vaccines research Deliverables Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis. The id.DRIVE Partnership launches its 2025–2026 Epidemiological Year with three studies Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform” (pre-print). Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVEplatform. Effectiveness of the AZD1222 Vaccine against COVID-19 hospitalisation in Europe: Final results from the COVIDRIVE test-negative case-control study.  Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: An id.DRIVE test-negative case-control study. Contact Newsroom2 Launch of the id.DRIVE respiratory syncytial virus (RSV) vaccine effectiveness study with the first site activation on 29 August 2024. id.DRIVE’s third site investigator meeting took place on 13 April in Vienna, Austria Don’t miss out on the latest id.DRIVE publications: three peer-reviewed articles on COVID-19 vaccine effectiveness based on data from the id.DRIVE partnership have been published in early 2025. id.DRIVE expands its study network to the United Kingdom with the activation of Imperial College London as a new study site id.DRIVE’s study network expands to France with the activation of Henri Mondor hospital site in Paris Poster presentation during ESCMID Global 2024 Participate Second in-person Site Investigator meeting COVIDRIVE expands its scope of studies and becomes id.DRIVE: new European partnership for burden and effectiveness studies on infectious diseases. Study investigator meeting in Copenhagen Second annual face-to-face COVIDRIVE Steering Committee meeting Site Investigators’ meeting Governance Contact CVE Reports The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE – a European initiative